Answers are grounded in this paper and cite their sources.
Chromatin remodelling SWI/SNF complexes are recurrently altered in malignancies, and some members were found to be associated with immune checkpoint blockade (ICB) response. However, it is unclear whether SWI/SNF complex genes as a collective factor have clinical relevance. Through pan‐cancer analysis of 8507 tumours across 26 types from The Cancer Genome Atlas, we demonstrate that SWI/SNF loss‐of‐function (LOF) mutations correlate with elevated immunogenicity markers, such as higher tumour mutational burden (TMB), neoantigen load, and microsatellite instability. SWI/SNF‐LOF tumours exhibited enriched CD8 + T cell and M1‐like macrophage infiltration, upregulation of major histocompatibility complex class genes, and increased expression of immunostimulators, immunoinhibitors, and chemokines. Crucially, in ICB‐treated patients across discovery ( n = 750) and validation ( n = 562) cohorts encompassing nine cancer types, SWI/SNF‐LOF status consistently predicted superior clinical outcomes, including prolonged overall survival, progression‐free survival, and higher objective response rates compared to non‐mutated tumours. Multivariate analysis confirmed SWI/SNF‐LOF as an independent ICB response predictor independent of TMB, age, sex, or cancer type. These findings identify SWI/SNF LOF mutations as promising biomarkers of an inflamed tumour microenvironment and favourable responses to ICB across multiple solid tumours.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: